Theratechnologies Inc. and Transfert Plus SEC have disclosed peptide-drug conjugates comprising a maytansinoid moiety linked to peptides targeting the sortilin (neurotensin NTR3; NT3; Gp95) receptor through a protease-cleavable linker reported to be useful for the treatment of cancer.
Novartis AG has described peptide-drug conjugates comprising cyclic peptides targeting HER2 (erbB2) covalently linked to a radiolabeled metal chelator through a linker reported to be useful for diagnosis and treatment of cancer.
University of Notre Dame du Lac has disclosed peptide-drug conjugates, their hydrogels and their self-assembling nanofibers comprising glucagon-like peptide 1 receptor (GLP-1R) and/or gastric inhibitory polypeptide receptor (GIPR) and/or glucagon receptor agonists linked to an amphiphile moiety through a hydrophobic or hydrophilic-comprising linker acting as vaccine adjuvants reported to be useful for the treatment of diabetes and obesity.
Proteinqure Inc. has received regulatory clearances from the U.FDA and Health Canada to initiate a phase I trial of lead candidate, PQ-203. The trial will begin in Canada and expand to U.S. sites later in 2025. The FDA also granted PQ-203 fast track designation for triple-negative breast cancer (TNBC).
Nibec Co. Ltd. announced May 28 the signing of a potential $435 million license deal for NP-201, its phase II-ready peptide-based pulmonary fibrosis therapy candidate, with an undisclosed U.S.-based biotech company.
Nibec Co. Ltd. announced May 28 the signing of a potential $435 million license deal for NP-201, its phase II-ready peptide-based pulmonary fibrosis therapy candidate, with an undisclosed U.S.-based biotech company.
Proteinqure Inc. has closed an $11 million series A financing round to support the initiation of the company’s first clinical trial for PQ-203, a first-in-class peptide-drug conjugate for triple-negative breast cancer (TNBC). The funds will also be used to advance additional pipeline programs in neurology and nephrology.
Peptide-drug conjugates (PDCs) are emerging as a promising alternative to antibody-drug conjugates (ADCs), offering enhanced tumor penetration and reduced immunogenicity. Carbonic anhydrase IX (CAIX) and epidermal growth factor receptor (EGFR) are both well-validated targets in oncology due to their role in cancer cell survival, invasion and migration.
Haisco Pharmaceutical Group Co. Ltd. has identified peptide-drug conjugates comprising a peptide targeting integrin αvβ3 (vitronectin) covalently bound to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
Mainline Biosciences (Shanghai) Co. Ltd. has described peptide-drug conjugates consisting of peptide targeting somatostatin receptors covalently bound to cytotoxic agents through a linker reported to be useful for the treatment of cancer.
